Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral compound that significantly reduces HBV (hepatitis B virus) DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) is a retinoic acid-inducible gene-I (RIG-I) agonist that activates intracellular innate immunity.

Physicochemical Properties

Molecular Formula	C20H29N8O10PS
Molecular Weight	604.5306
Exact Mass	604.146
Elemental Analysis	C, 39.74; H, 4.84; N, 18.54; O, 26.47; P, 5.12; S, 5.30
CAS #	2172788-92-8
Related CAS #	Inarigivir;475650-36-3
PubChem CID	162623408
Appearance	White to light yellow solid powder
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	9
Heavy Atom Count	40
Complexity	1010
Defined Atom Stereocenter Count	7
SMILES	S=P(O)(OC[C@@H]1[C@H](C[C@H](N2C=NC3=C(N)N=CN=C23)O1)O)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]1OC)N1C=CC(NC1=O)=O.N
InChi Key	CAUBLFJDYDLFRY-NJCNYLKWSA-N
InChi Code	InChI=1S/C20H26N7O10PS.H3N/c1-33-16-15(10(5-28)36-19(16)26-3-2-12(30)25-20(26)31)37-38(32,39)34-6-11-9(29)4-13(35-11)27-8-24-14-17(21)22-7-23-18(14)27;/h2-3,7-11,13,15-16,19,28-29H,4-6H2,1H3,(H,32,39)(H2,21,22,23)(H,25,30,31);1H3/t9-,10+,11+,13+,15+,16+,19+,38?;/m0./s1
Chemical Name	O-(((2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl) O-((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-yl) S-hydrogen phosphorothioate, ammonia salt
Synonyms	Inarigivir ammonium; ORI-9020; ORI 9020; ORI9020; SB-40; SB-9000; SB9000, SB-9000.
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Target: HBV[1].
ln Vitro	The nucleos(t)ide analogs authorized for the treatment of chronic hepatitis B are all susceptible to resistance markers when it comes to HBV variations that are active against inarigivir (SB 9200)[2].
ln Vivo	Inarigivir (100 mg/kg/day, i.p.) exhibits anti-HBV action and dramatically lowers viral DNA in the liver. Treatment does not result in a decrease in serum HBV DNA. HBV RNA levels in the liver, HBeAg levels in the blood, and mean titers of HBsAg are unaffected by inarigivir. Based on liver HBV DNA levels, the lowest effective dose is shown to be between 1.6 and 0.5 mg/kg/day[1].
Animal Protocol	Animal/Disease Models: Mice[1] Doses: 100 mg/kg. Route of Administration: IP, daily. Experimental Results: Dramatically diminished viral DNA in the liver and shows anti-HBV activity similar ADV positive control.
References	[1]. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48(6):2318-20. [2]. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos(t)ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro.

Solubility Data

Solubility (In Vitro)	H2O : 100 mg/mL (165.42 mM) DMSO : 100 mg/mL (165.42 mM)
Solubility (In Vivo)	Solubility in Formulation 1: 100 mg/mL (165.42 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6542 mL	8.2709 mL	16.5418 mL
	5 mM	0.3308 mL	1.6542 mL	3.3084 mL
	10 mM	0.1654 mL	0.8271 mL	1.6542 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.